1155-57-3

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 62-53-3 aniline 
• 793-19-1 bis(2-methoxycarbonylethyl)benzylamine 
• 100-46-9 benzylamine 
• 4783-65-7 N-benzyl-2-piperidinone 
• 108-20-3 di-isopropyl ether 

Downstream Products

• 215713-91-0 1-phenyl-6-benzyl-1,2,3,4,5,6,7,8-octahydro-1,6-naphthiridine 
• 1155-56-2 1-benzyl-N-phenylpiperidin-4-amine 
• 857843-39-1 1-benzyl-4'-methyl-3',4'-dihydro-1'-H-spiro[piperidine-4,2'-quinoline] 
• 95869-86-6 N-(1-benzyl-piperidin-4-yl)-N-phenyl-benzamide 
• 857843-36-8 4-allyl-1-benzyl-N-phenylpiperidin-4-amine 

Relevant academic research and scientific papers

Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls

A series of fentanyl analogues modified at the phenyl group of the phenethyl with alkyl and/or hydroxyl and alkoxy, and the phenyl group in the anilido moiety replaced with benzyl or substituted benzyl, were synthesized. The in vitro opioid receptor functional activity of these compounds was evaluated by assessment of their ability to modulate forskolin-stimulated cAMP accumulation and by their ability to induce β-arrestin2 recruitment. Compound 12 is a potent μ-opioid (MOP) receptor agonist, a potent κ-opioid (KOP) receptor antagonist with weak β-arrestin2 recruitment activity. Compounds 10 and 11 are potent MOP receptor agonists with weak δ-opioid (DOP) receptor antagonist activity and moderate KOP receptor antagonist activity as well as weak β-arrestin2 recruitment activity at the MOP receptor. These compounds are promising leads for discovery of potent opioid analgesics with reduced side effects relative to clinically available strong opioid analgesics.

1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to 1,9-diazaspiro undecane compounds having this pharmacological activity, to processes of

3',4'-dihydrospiro[piperidine-4,2'-(1'H)quinoline] derivatives as new antioxidant agents with acetylcholinesterase inhibitory property

In vitro radical-cation scavenging capacity and anti-AChE activities of 19 piperidine derivatives, including dihy-drospiro[piperidine-4,2'(1'H)quinolines] 7-19 and their precursor 4-allyl-4-arylaminopiperidines 1-6 were reported. Their data of bioassays a

Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain

Acids 9a-f as possible bivalent ligands designed as a structural combination of opioid μ-agonist (Fentanyl) and NSAID (Indomethacin) activities and produced compounds which were tested as analgesics. The obtained series of compounds exhibits low affinity and activity both at opioid receptors and as cyclooxygenase (COX) inhibitors. One explanation of the weak opioid activity could be stereochemical peculiarities of these bivalent compounds which differ significantly from the fentanyl skeleton. The absence of significant COX inhibitory properties could be explained by the required substitution of an acyl fragment in the indomethacin structure for 4-piperidyl.

Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at μ and δ opioid receptors

New 4-anilidopiperidine analogues in which the phenethyl group of fentanyl was replaced by several aromatic ring-contained amino acids (or acids) were synthesized to study the biological effect of the substituents on μ and δ opioid receptor interactions. These analogues showed broad (47 nM-76 μM) but selective (up to 17-fold) binding affinities at the μ opioid receptor over the δ opioid receptor, as predicted from the message-address concept.

An efficient synthesis of new 1-H-4′-methyl-3′,4′-dihydrospiro[piperidine-4,2′(1′H)quinoline] scaffolds

Efficient synthesis of new 3′,4′-dihydrospiro[piperidine-4,2′(1′H)quinolines] by a four step synthetic route based on 1-benzyl-4-piperidone reactivity is reported.

Synthesis and conformational study of 1,2,3,4,5,6,7,8-octahydro-1,6- naphthiridines

A new class of endocyclic enamines, 1,6-disubstituted 1,2,3,4,5,6,7,8- octahydro-1,6-naphthiridines, was synthesized from 4-piperidone imines by successive subjecting the latter to lithiation with lithium diethylamide, to alkylation with 1-bromo-3-chloropropane, and to intramolecular cyclization. All stages were carried out as a unique process without isolation of the intermediate compounds. A thorough optimization of the process conditions, workup, and product storage was carried out. The conformational study of 1,6-disubstituted 1,2,3,4,5,6,7,8-octahydro-1,6-naphthiridines was performed. Pleiades Publishing, Inc. 2006.

Novel hexahydrospiro[piperidine-4,1′-pyrrolo[3,4-c]pyrroles: Highly selective small-molecule nociceptin/orphanin FQ receptor agonists

Novel hexahydrospiro[piperidine-4,1′-pyrrolo[3,4-c]pyrroles that act as potent and selective orphanin FQ/nociceptin (N/OFQ) receptor (NOP) agonists were identified. The best compound, (+)-5a, potently inhibited 3H-N/OFQ binding to the NOP recep

A new series of M3 muscarinic antagonists based on the 4-amino-piperidine scaffold

A series of 4-amino-piperidine containing molecules have been synthesized and structure-affinity relationship toward the M3-muscarinic receptor has been investigated. Chemical modulations provided molecules with Ki for the human M3-R up to 1 nM with variable selectivity (3- to 40-fold) over the human M2-R. Compounds 2 (pA2=8.3, 8.6) demonstrates in vitro on guinea pig bladder and ileal strips potent anticholinergic properties and tissue selectivity.

A simple and convenient route to 1,2,3,4,5,6,7,8-octahydro-1,6- naphthyridines

A simple and convenient synthetic approach to the new series of 1,2,3,4,5,6,7,8-octahydro-1,6-naphthyridines 1a-j has been developed. This was achieved via a one-pot process combining metalated 4-piperidinonimine alkylation and intramolecular cyclization.